Navigating Federal Trade Commission (FTC) and Food and Drug Administration (FDA) regulations for dietary supplements requires technical precision and absolute alignment between marketing copy and underlying clinical data. U.S. regulation of dietary supplement promotion is split between two federal agencies.
Food and Drug Administration (FDA): primary jurisdiction over supplement safety, physical labeling, packaging, and manufacturing under the Dietary Supplement Health and Education Act of 1994 (DSHEA).
Federal Trade Commission (FTC): primary authority over dietary supplement advertising across every promotional channel — websites, social media, influencer endorsements, affiliate links, podcast reads, and email campaigns.
Under Section 5 of the FTC Act (15 U.S.C. § 45), deceptive or unfair advertising is illegal. For health-related representations, the FTC enforces a rigorous standard: any claim about a product's safety, efficacy, or health benefit must be backed by competent and reliable scientific evidence before the claim is made — not after.
For the Supplement Facts panel itself - separate from advertising substantiation - see Supplement Facts Label Check - Complete 21 CFR §101.36 Panel Guide.
What Is a Structure-Function Claim - and What It Is Not
Compliance starts with the legal boundary separating three categories of dietary supplement representation: structure-function claims, disease claims, and health claims.
| Claim type | Definition | Legal requirement |
|---|---|---|
| Structure-function | Describes effect on normal body structure or function | FDA notification within 30 days + mandatory disclaimer |
| Health claim | Links a substance to reduced risk of a specific disease | Requires prior FDA authorization (SSA) or qualified claim status |
| Disease claim | Claims to treat, cure, mitigate, or prevent a disease | Prohibited for supplements — treated as an unapproved drug |
Structure-function claims
A structure-function claim describes the role of a nutrient or dietary ingredient in affecting the normal structure or function of the human body, or characterizes the mechanism by which it maintains that structure or function. These claims are authorized under Section 403(r)(6) of the FD&C Act (21 U.S.C. § 343(r)(6)), as amended by DSHEA.
- Focuses exclusively on supporting or maintaining normal, healthy bodily function.
- Does not reference a disease, pathological state, or specific symptom of disease.
- Requires FDA notification within 30 days of the claim entering interstate commerce.
- Requires the mandatory statutory disclaimer on labeling and point-of-sale materials: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” (21 CFR § 101.93)
Compliant structure-function examples
“Calcium helps build and maintain strong bones.” • “Glucosamine helps support healthy joint mobility and cartilage integrity.” • “Helps maintain blood sugar levels already within the normal range.” • “Supports a healthy mood and normal physiological response to daily stress.”
Disease claims
A disease claim expressly or impliedly states that a product can prevent, treat, cure, mitigate, or diagnose a specific disease or medical condition. Dietary supplements are legally prohibited from making disease claims. A supplement that makes one is classified by the FDA as an unapproved new drug under Section 201(g)(1)(B) of the FD&C Act — exposing the company to warning letters, civil penalties, injunctions, product seizures, and mandatory refunds.
Unlawful examples: “Reduces joint pain and chronic inflammation associated with arthritis.” • “Lowers high blood pressure and reduces arterial plaque.” • “Formulated to treat clinical depression and severe anxiety.” • “Protects against viral respiratory infections.”
Health claims
A health claim links a substance to a reduced risk of a specific disease or health-related condition. Unlike structure-function claims, health claims require explicit prior FDA authorization or acknowledgment before use — either meeting the Significant Scientific Agreement (SSA) standard, or qualifying for an FDA Letter of Enforcement Discretion as a Qualified Health Claim.
Authorized example: “Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis.” Qualified example: “Inconsistent and inconclusive scientific evidence suggests that diets with adequate magnesium may reduce the risk of high blood pressure (hypertension)...”
The FTC Evidence Standard - Competent and Reliable Scientific Evidence
The FTC requires advertisers to hold a “reasonable basis” for every express and implied claim before it is made. For health, safety, and efficacy claims, that reasonable basis must consist of competent and reliable scientific evidence — defined in the FTC's Health Products Compliance Guidance and administrative precedent as:
“Tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, conducted and evaluated in an objective manner by qualified individuals, using procedures generally accepted in the profession to yield accurate and reliable results.”
In practice, the FTC expects substantiation grounded in well-conducted human clinical testing that reflects these methodological controls:
- Randomization — subjects are assigned to treatment or control groups strictly at random, eliminating selection bias.
- Double-blinding — neither participants nor evaluators know who received the active formulation versus the placebo.
- Placebo control — the active formulation is tested against an inert control to isolate the true biological effect.
- Statistical significance — results typically must reach p ≤ 0.05, showing the effect is unlikely to be chance.
- Clinical meaningfulness — the outcome must translate to a real, noticeable benefit, not a trivial biomarker shift.
- No post-hoc data mining — end points must be set before the study runs; scraping a positive result from a subgroup analysis after a trial fails does not count as competent and reliable evidence.
The Evidence Hierarchy - How Different Study Types Are Weighted
The FTC evaluates evidence using a strict hierarchy. Higher-tier clinical data carries substantial weight; lower-tier observational or laboratory research cannot stand alone to substantiate a health claim.
Animal models and cell culture assays are valuable in early-stage research, but they don't account for human digestion, hepatic metabolism, absorption rates, or blood-brain barrier permeability. Advertising a human health benefit based solely on rodent or test-tube data — without supporting human clinical evidence — is deceptive advertising under FTC law.
| Tier | Study type | FTC weight |
|---|---|---|
| 1 | Randomized, double-blind, placebo-controlled human trials (RCTs) | Gold standard — essential for substantiating human efficacy claims |
| 2 | Human observational / epidemiological studies | Secondary support — shows correlation, not causation, on its own |
| 3 | Animal (in vivo) studies | Mechanistic only — cannot substantiate human outcomes alone |
| 4 | In vitro / in silico assays | Preliminary screening only — no standalone legal weight |
How Many Studies Do You Actually Need?
A persistent misconception is that a fixed numerical threshold exists — “you always need two RCTs.” The FTC has never established a rigid, categorical study-count requirement. Both its 1998 Dietary Supplements Guide and its 2022 Health Products Compliance Guidance state that adequacy depends on the totality of the scientific context, not a fixed count.
Efficacy claims vs. establishment claims
- Efficacy claims (e.g., “Helps maintain healthy joint mobility”) require competent and reliable scientific evidence — typically at least one well-designed, statistically significant human RCT matching the product's dose and formulation.
- Establishment claims (e.g., “Clinical studies prove...” or “Medically proven...”) require the marketer to possess the exact level of evidence stated. Claiming “studies prove” on the strength of one ambiguous study violates FTC law.
The totality of evidence rule
Marketers cannot cherry-pick two favorable small studies while ignoring five larger, well-conducted trials that showed null or contradictory results. If the broader scientific consensus contradicts a claim, the evidence is legally insufficient no matter how many isolated positive studies are cited. The FTC also emphasizes replication: independent confirmation of a finding by separate research teams substantially reduces the risk that an initial positive result was methodological noise or chance.
The judicial boundary — POM Wonderful v. FTC
POM Wonderful LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015), set the outer limits of FTC authority here. The D.C. Circuit upheld the FTC's requirement that POM needed randomized controlled human trials to back its disease-prevention claims for pomegranate juice — but struck down the FTC's attempt to impose a mandatory, categorical floor of two RCTs for all future disease-related claims. The court held that a rigid two-RCT rule violated commercial speech protections under the First Amendment when one high-quality RCT, considered alongside the broader body of science, could be sufficient.
The Dosage and Population Matching Problem
A frequent point of failure occurs when a brand cites a valid, high-quality human study but fails to match that study's parameters to its actual commercial product.
| Clinical study parameters | Your commercial product |
|---|---|
| Active dose: 600 mg daily | Active dose: 50 mg daily |
| Form: standardized extract (95%) | Form: generic crude herb powder |
| Target population: adults aged 55–75 | Target population: healthy adults aged 18–30 |
Dosage mismatch (“fairy-dusting”)
If a trial shows joint mobility benefits at 600 mg daily of a standardized extract, that study cannot substantiate a claim for a product delivering only 50 mg per serving. Including a sub-therapeutic amount of an ingredient purely for label appeal invalidates the scientific connection. Product dosage must meet or exceed the dose shown effective in the underlying trial.
Chemical form and bioavailability
Results from a patented, highly bioavailable extract cannot be extrapolated to a generic, unstandardized version of the same raw material — for example, applying data from a water-soluble curcumin complex to a basic turmeric root powder, or from magnesium L-threonate (which crosses the blood-brain barrier) to plain magnesium oxide.
Target population
A study on one population cannot automatically be generalized to another. Pain-reduction data from patients with diagnosed osteoarthritis does not translate to a “post-workout recovery” claim for healthy young athletes, and bone-density data from post-menopausal women does not support a wellness claim aimed at men in their twenties.
What a Substantiation Dossier Contains - The Six Components
Before bringing product claims to market, a brand should compile a written substantiation dossier that can withstand an FTC Civil Investigative Demand or FDA warning letter. It has six components:
- Claim mapping matrix — every express and implied claim across all marketing assets: labels, website copy, product pages, video scripts, social ads, influencer briefs, and meta descriptions.
- Finished product specification — the exact active formulation per serving, including supplier, standardization percentage, bioassay profile, and delivery form.
- Systematic literature search — a documented search strategy across PubMed, Cochrane, and Embase, capturing both supporting and contradicting studies to satisfy the totality of evidence rule.
- Clinical quality and risk-of-bias assessment — evaluation of each primary study against trial registration, sample size, drop-out rate, blinding, baseline equivalence, and statistical power.
- Dose-matching and extrapolation analysis — explicit comparison of product dose, delivery form, and target demographic against the supporting trials.
- Executive conclusion and regulatory sign-off — synthesis of the totality of evidence, a risk rating for each claim, and written sign-off from regulatory affairs or counsel.
Seven Common Substantiation Mistakes That Trigger FTC Scrutiny
The FTC actively monitors digital and social channels for deceptive health claims. These seven mistakes recur across recent enforcement actions.
Mistake 1: Using “disease code words” in structure-function copy
The pitfall: Softening a drug claim with words like “alleviates joint pain,” “combats inflammation,” or “reduces anxiety.” The FTC and FDA treat pain, inflammation, and anxiety as symptoms of recognized medical conditions.
Real enforcement example: FTC v. ZyCal Bioceuticals Healthcare Co., Inc., No. 1:20-cv-10249 (D. Mass., complaint filed Feb. 2020; order finalized Feb. 2023). ZyCal marketed its “Cyplexinol” ingredient as able to grow bone and cartilage and relieve joint pain from osteoarthritis and osteoporosis. The court order bars the defendants from making bone, cartilage, or pain-relief claims unless supported by randomized controlled human clinical trials.
Mistake 2: Assuming customer testimonials and reviews are exempt
The pitfall: Publishing or amplifying customer reviews that claim a product cured an illness. Brands often assume user-generated content isn't their liability — it is.
Real enforcement example: FTC v. Amare Global Holdings, Inc. et al. (contempt motion filed June 2026). The FTC alleges Amare Global, its former Chief Science Officer Shawn Talbott, and other principals violated a 2005 order barring unsubstantiated health claims, marketing supplements as able to lower cortisol and treat depression, anxiety, and ADHD in children and adults.
Mistake 3: Marketing unsubstantiated physical growth or development claims
The pitfall: Claiming a supplement can alter structural growth — for example, increasing height in children — without rigorous, peer-reviewed human clinical proof.
Real enforcement example: In re TruHeight (Vanilla Chip LLC), FTC Matter No. 242-3093 (complaint April 2026; final order approved July 2026). The FTC alleged TruHeight lacked competent and reliable scientific evidence for claims like “The Only Supplement Clinically Proven to Help Height Growth,” and used fake and incentivized reviews. The final order imposed a $4 million judgment, partially suspended to a $750,000 payment.
Mistake 4: Sub-therapeutic dosing (“fairy-dusting”)
The pitfall: Formulating a product with a token amount of a branded ingredient — say, 25 mg — while citing research conducted at 500 mg daily.
Real enforcement example: FTC Notice of Penalty Offenses Concerning Substantiation of Product Claims (April 13, 2023). The FTC sent notices to roughly 670 supplement, OTC drug, homeopathic, and functional food marketers, warning that civil penalties of up to $50,120 per violation apply to claims not backed by evidence matching the actual formulation and dose sold.
Mistake 5: Relying on a single, methodologically flawed study
The pitfall: Using one study with high drop-out rates, no baseline comparison, or missing blinding controls to support a broad efficacy claim.
Real enforcement example: In the Amare Global contempt motion, the FTC highlighted that a key study cited by the company compared treatment and placebo group endpoints without measuring baseline levels — a fundamental design flaw that undermines any claim of statistical significance.
Mistake 6: Extrapolating animal or in vitro data to humans
The pitfall: Advertising a human benefit — “Boosts memory and cellular longevity” — based entirely on rodent studies or cell-culture assays.
Real enforcement example: FTC Health Products Compliance Guidance (December 2022) flags this pattern directly: marketers of botanical extracts relying on test-tube or animal models to claim anti-aging or memory benefits in humans, without human clinical data, do not meet the competent and reliable evidence standard.
Mistake 7: Misleading use of third-party books, articles, and links
The pitfall: Linking a product page or social post to a third-party book or article describing an ingredient's disease-curing properties.
Real enforcement example: Under longstanding FTC guidance, an advertiser is responsible for implied claims created by referenced third-party material. Linking to content titled, for example, “The Miracle Cancer Cure” about an ingredient in the product creates advertiser liability for the implied disease claim, even without saying it directly.
Your Execution Options: In-House, Consultant, or Automated Substantiation
Building a durable substantiation process comes down to three operational paths. The right choice depends on product line complexity, internal regulatory capability, speed-to-market needs, and budget.
| Path | Cost | Turnaround | Risk profile |
|---|---|---|---|
| In-house review | Medium (payroll overhead) | Slow — weeks per SKU | Variable — inconsistent objectivity |
| Regulatory consultant / counsel | High — $5,000–$15,000+ per SKU | 2–6 weeks | Low — bespoke legal defense |
| Automated substantiation | Low — per-job pricing | Under an hour | Low — structured, evidence-ranked output |
Path 1: In-house review
Internal regulatory, marketing, or QA staff handle claim review and dossier assembly. Cost is moderate in payroll terms, but thorough literature searches and dossier compilation typically take weeks per SKU, and internal teams can struggle to stay objective under marketing pressure to keep risky copy live.
Path 2: Regulatory consultants and legal counsel
Outside regulatory attorneys or specialized consultants audit copy and produce a formal legal substantiation report. Fees typically run $500–$1,000+ per hour, totaling $5,000–$15,000+ per product line, with 2–6 week turnarounds. This path buys bespoke legal analysis and attorney-client privilege — valuable during an actual investigation, but slow and expensive for routine claim checks.
Path 3: Automated substantiation platforms
Purpose-built compliance software parses clinical literature, matches product formulation against the FDA/FTC evidence hierarchy, and generates a structured dossier — automatically filtering out low-tier data and flagging dosage or population mismatches. It won't replace bespoke courtroom advocacy, but it's a reliable, fast first-line audit for brands substantiating claims across multiple SKUs.
If you want to check where your current claims stand, EviClaim runs a substantiation check against the FDA/FTC evidence hierarchy and returns a structured dossier in under an hour. The first job is free.
References
- FTC Health Products Compliance Guidance (December 2022), Health Products Compliance Guidance.
- FTC Policy Statement Regarding Advertising Substantiation, FTC advertising substantiation policy.
- U.S. Food and Drug Administration (FDA), Small Entity Compliance Guide on Structure/Function Claims, FDA structure/function claims guide.
- U.S. Food and Drug Administration (FDA), Guidance for Industry — Substantiation for Dietary Supplement Claims Under Section 403(r)(6), FDA §403(r)(6) substantiation guidance.
- Certain Types of Statements for Dietary Supplements, 21 CFR § 101.93.
- POM Wonderful LLC v. FTC, 777 F.3d 478 (D.C. Cir. 2015), POM Wonderful v. FTC.
- U.S. Federal Trade Commission, FTC Order to Bar ZyCal Bioceuticals from Deceptive Health Marketing (Feb. 2023), FTC ZyCal press release.
- U.S. Federal Trade Commission, FTC Takes Action Against TruHeight for Deceptive and Unsubstantiated Advertising (April 2026), FTC TruHeight press release.
- U.S. Federal Trade Commission, FTC Files Contempt Motion Against Amare Global and Three Individuals (June 2026), FTC Amare Global press release.
- U.S. Federal Trade Commission, FTC Warns Almost 700 Marketing Companies About Substantiation (April 2023), FTC penalty offenses notice.